Navigation Links
Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania
Date:5/20/2013

ROCKVILLE, Md., May 20, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that Eva Feldman , MD, PhD, principal investigator, presented updated Phase I data from its spinal cord-derived human neural stem cell (NSI-566) trial in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig 's disease) at the neuro diabetes special medical symposium in Bucharest, Romania, on Friday. In a talk called "Recent Therapeutic Advances in Stem Cell Therapy," Dr. Feldman outlined the design of the trial, which started with unilateral lumbar injections in non-ambulatory patients, and eventually progressed to bilateral lumbar injections, combined with unilateral cervical spinal injections, in ambulatory patients.  She presented detailed data on all 15 patients and 18 procedures in the trial (three patients received additional transplants), including the clinically validated Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) ratings. The ALSFRS is a scale used to assess disability in ALS patients.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

Dr. Feldman reported that six study patients have a stable, very slowly progressing or improved disease course at more than 700-to-approximately-850 days post-surgery. Furthermore, she stated that these patients all share two common clinical characteristics:  They had no bulbar features of ALS, a form of the disease that destroys motor neurons in the corticobulbar area of the brainstem in the early stages and typically progresses faster than the limb-onset ALS. Additionally, these patients all received stem cell transplantation early in the course of their disease (at an average of 2 years, 1 month after symptom-onset). Two of the patients showing stabilization or improvement were
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neuralstem Updates ALS Stem Cell Trial Progress
2. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
3. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
6. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
7. Neuralstem Announces Proposed Public Offering
8. Neuralstem to Raise $7.0 Million in Registered Direct Offering
9. Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
10. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
11. Neuralstem Secures $8 Million In Debt Financing From Hercules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , and MARSEILLE, France , July ... Exclusive global license from University of Tokyo enables development ... (NGS) gene panels, for blood cancers  Mutations ... indicate favorable prognosis for patients with bone marrow disorders ... for developing companion diagnostics to guide treatment with new ...
(Date:7/24/2014)... 2014 Amgen (NASDAQ: AMGN ) today ... on Tuesday, July 29, 2014, after the close of the ... conference call with the investment community at 2 p.m. PT. ... A. Bradway , chairman and chief executive officer, and other ... of the conference call will be simultaneously broadcast over the ...
(Date:7/24/2014)... 2014 Many new dentists who are opening their ... that their practice will be a success. DentalDisposables.net is here ... use the most can make all the difference. Dentistry is ... discovered that purchasing discount dental supplies can make ... to successful dentists across the United States ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2Dental Supplies Online is Key to Dental Success...Really! 2
... conjunction with its first quarter 2011 earnings release (expected to ... Inc. (NYSE: CVD ) is pleased to invite ... will be broadcast live over the Internet on Thursday, May ... 2011 Earnings Webcast and Slide PresentationWhen: , Thursday, May 5, ...
... PLYMOUTH, Minn., April 5, 2011 NuAire, a ... International to bring a complete line of laboratory ... International, previously BMS International, has distributed NuAire laboratory ... biotechnology experience to the world,s top research, hospital, ...
Cached Medicine Technology:
(Date:7/24/2014)... off nighttime production of the hormone melatonin, renders breast ... cancer drug, says a new study by Tulane University ... Melatonin Disruption by Exposure to Light at Night Drives ... in the journal Cancer Research , is the ... success of tamoxifen in treating breast cancer. , , ...
(Date:7/24/2014)... The report, “Content Delivery Networks (CDN) ... various sub-segments with an in-depth analysis and forecasting ... restraints for this market with insights on trends, ... tables and 36 figures spread through 157 pages ... Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . , Early ...
(Date:7/24/2014)... Amy Norton HealthDay Reporter THURSDAY, ... teenage boy may be dead wrong, according to a small study ... In interviews with 33 boys between the ages of 14 and ... a girl for the closeness and trust. Very few boasted about ... a relationship with a girl. "In our culture, we have ...
(Date:7/24/2014)... Pools and beaches are the place to be ... especially for small children, so Amica Insurance is ... the Centers for Disease Control and Prevention, children between the ... water-related injuries and deaths. It’s important to know the best ... is offering the following tips from the American Red Cross:, ...
(Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- Drinking caffeine ... affect roughly two-thirds of women as they go through ... are preliminary, our study suggests that limiting caffeine intake ... bothersome hot flashes and night sweats," said researcher Dr. ... the Mayo Clinic in Rochester, Minn. But caffeine ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Is Coffee Aggravating Your Hot Flashes? 2
... Inc. (Nasdaq and SWX: BMRN) today announced that,Jean-Jacques ... a,conference call and webcast on Tuesday, February 26, ... quarter and full year 2007 financial results., ... International Dial-in Number: 617.597.5312 Participant ...
... Present at Merrill Lynch,s Global Pharmaceutical Conference Feb. ... ... today that it will host a conference call and live webcast on,Wednesday, Feb. ... nine months ended Dec. 31, 2007. The Company also will provide,an operational and ...
... Mrs. Bojan M. Kuure, of,Jakobstad, Finland, has ... for her outstanding contributions and achievements in the,field ... About Mrs. Bojan M. Kuure, Mrs. ... a dedicated registered,nurse. She obtained a Special Registered ...
... Feb. 5 Watson,Pharmaceuticals, Inc. (NYSE: WPI ... the company expects to initiate shipments of,alendronate sodium ... dosage strengths when,Fosamax(R) loses market exclusivity, which is ... February 6, 2008. Alendronate sodium is the generic,version ...
... Feb. 5 Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical ... cancer, announced today that it will,host a conference ... Time on,Tuesday, February 19, 2008 to discuss the ... A press release will be issued before the ...
... Youth may be more,likely victimized while using instant messenger ... new research this week reports., The study, conducted ... Kids and Kimberly Mitchell of the University of New,Hampshire, ... youth are most likely,to experience sexual solicitation and harassment. ...
Cached Medicine News:Health News:BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET) 2Health News:Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007 2Health News:Bojan M. Kuure Recognized by Strathmore's Who's Who Worldwide Publication 2Health News:Watson to Distribute Alendronate Tablets 2Health News:Favrille to Host Conference Call and Live Webcast to Discuss Fourth Quarter and Year End 2007 Financial Results on February 19, 2008 2Health News:Are Social Networking Sites Endangering Young Teens? Study Finds Maybe Not 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: